Race releases cardioprotection market potential data
Released 03 Apr 23
Latest announcements
Announcement summary
Race releases cardioprotection market potential data
- Triangle Insights conducted blinded primary research with stakeholders to investigate Zantrene’s commercial potential as cardio-protective and anti-cancer agent within key cancer types where anthracyclines are typically used
- Assessment suggests that Zantrene is well-positioned for use in metastatic breast cancer broadly, and within the neoadjuvant setting for HR+/HER2- and triple negative breast cancer (HR-/HER2), relative to the profile assessed
- Significant opportunity: may offer >$5B USD if anti-cancer efficacy is demonstrated, or ~$1B USD as a supportive care cardio-protective therapeutic
Ask a question
Your question will be sent privately to Race Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Race Oncology a question about this announcement.